Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Merck
US Army
Fish and Richardson
Colorcon
Accenture
Healthtrust
Julphar
Farmers Insurance
Mallinckrodt

Generated: August 21, 2017

DrugPatentWatch Database Preview

EXJADE Drug Profile

« Back to Dashboard

What is the patent landscape for Exjade, and when can generic versions of Exjade launch?

Exjade is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty-four countries.

The generic ingredient in EXJADE is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.

Summary for Tradename: EXJADE

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list61
Clinical Trials: see list27
Patent Applications: see list316
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EXJADE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-001Nov 2, 2005ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-003Nov 2, 2005ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-002Nov 2, 2005ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-003Nov 2, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-001Nov 2, 2005ABRXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EXJADE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-001Nov 2, 2005► Subscribe► Subscribe
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-003Nov 2, 2005► Subscribe► Subscribe
Novartis
EXJADE
deferasirox
TABLET, FOR SUSPENSION;ORAL021882-002Nov 2, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EXJADE

Drugname Dosage Strength RLD Submissiondate
deferasiroxTablets125 mg, 250 mg, and 500 mgExjade10/28/2011

Non-Orange Book Patents for Tradename: EXJADE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,723,742 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EXJADE

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)9749395► Subscribe
Australia718037► Subscribe
South Korea20000022222► Subscribe
Canada2255951► Subscribe
Georgia, Republic ofP20084355► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EXJADE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C 035/2006Ireland► SubscribeSPC 035/2006: 20070528, EXPIRES: 20210827
0914118/01Switzerland► SubscribePRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
0248Netherlands► Subscribe300248, 20170624, EXPIRES: 20210827
2007001,C0914118Lithuania► SubscribePRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828
2006 00035Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Federal Trade Commission
QuintilesIMS
Covington
Healthtrust
Cantor Fitzgerald
Baxter
McKesson
US Army
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot